Elizabeth C Townsend1, Grace Y Zhang1, Rabab Ali1, Marian Firke1, Mi Sun Moon1, Ma Ai Thanda Han1, Benjamin Fram2, Jeffrey S Glenn2,3,4, David E Kleiner5, Christopher Koh1, Theo Heller1. 1. Liver Diseases Branch, National Institute of Diabetes, Digestive, and Kidney Diseases, Bethesda, Maryland, USA. 2. Department of Medicine, Stanford University, Stanford, California, USA. 3. Department of Microbiology and Immunology, Stanford University, Stanford, California, USA. 4. Department of Medicine, Veterans Administration Medical Center, Palo Alto, California, USA. 5. Laboratory of Pathology, National Cancer Institute, Bethesda, Maryland, USA.
Abstract
BACKGROUND AND AIM: Hepatitis delta virus (HDV) infection is the most rapidly progressive chronic viral hepatitis. Little is understood about the immune responses to HDV. This study aims to characterize the systemic immune environments of hepatitis B virus (HBV) and HDV patients at various disease stages. METHODS: A total of 129 subjects were evaluated: 53 HBV, 43 HDV, and 33 healthy controls. HBV and HDV subjects were categorized by aspartate aminotransferase to platelet ratio index (APRI) into mild (APRI < 0.5), moderate, and severe (APRI > 1.0). Serum cytokines and immune markers were assessed at a single treatment-naïve time-point. RESULTS: Type 1 cytokines are elevated in both HBV and HDV. Both groups show higher tumor necrosis factor-α (TNF-α), interleukin (IL)-12p40, and C-X-C motif chemokine ligand 9 when compared with controls (all P < 0.05). However, only HBV group displayed elevated γ-interferon compared with controls. Type 2 cytokines are elevated in HBV. HBV group shows higher IL-4, IL-13, and C-C motif chemokine ligand (CCL) 26 compared with healthy controls and HDV. Chemokines CCL2 and CCL13 are lower in HDV. When assessing ratios, HDV displays higher γ-interferon/IL-4, TNF-α/IL-4, and TNF-α/IL-13 ratios than HBV and controls. CONCLUSION: Hepatitis B virus and HDV subjects show similarly elevated type 1 cytokines. HDV subjects display relatively lower type 2 cytokines. These differences in the systemic immune environments, particularly the predominance of type 1 responses, may contribute to the comparatively rapid progression of HDV disease. Characterization of the imbalance in type 1 and type 2 immunity unique HDV has the potential to provide immunological insights for designing therapeutic targets in HDV-associated disease progression.
BACKGROUND AND AIM: Hepatitis delta virus (HDV) infection is the most rapidly progressive chronic viral hepatitis. Little is understood about the immune responses to HDV. This study aims to characterize the systemic immune environments of hepatitis B virus (HBV) and HDVpatients at various disease stages. METHODS: A total of 129 subjects were evaluated: 53 HBV, 43 HDV, and 33 healthy controls. HBV and HDV subjects were categorized by aspartate aminotransferase to platelet ratio index (APRI) into mild (APRI < 0.5), moderate, and severe (APRI > 1.0). Serum cytokines and immune markers were assessed at a single treatment-naïve time-point. RESULTS: Type 1 cytokines are elevated in both HBV and HDV. Both groups show higher tumor necrosis factor-α (TNF-α), interleukin (IL)-12p40, and C-X-C motif chemokine ligand 9 when compared with controls (all P < 0.05). However, only HBV group displayed elevated γ-interferon compared with controls. Type 2 cytokines are elevated in HBV. HBV group shows higher IL-4, IL-13, and C-C motif chemokine ligand (CCL) 26 compared with healthy controls and HDV. Chemokines CCL2 and CCL13 are lower in HDV. When assessing ratios, HDV displays higher γ-interferon/IL-4, TNF-α/IL-4, and TNF-α/IL-13 ratios than HBV and controls. CONCLUSION:Hepatitis B virus and HDV subjects show similarly elevated type 1 cytokines. HDV subjects display relatively lower type 2 cytokines. These differences in the systemic immune environments, particularly the predominance of type 1 responses, may contribute to the comparatively rapid progression of HDV disease. Characterization of the imbalance in type 1 and type 2 immunity unique HDV has the potential to provide immunological insights for designing therapeutic targets in HDV-associated disease progression.
Authors: Jan Grabowski; Cihan Yurdaydìn; Kalliopi Zachou; Peter Buggisch; Wolf P Hofmann; Jerzy Jaroszewicz; Verena Schlaphoff; Michael P Manns; Markus Cornberg; Heiner Wedemeyer Journal: Liver Int Date: 2011-07-15 Impact factor: 5.828
Authors: M K Gately; D M Carvajal; S E Connaughton; S Gillessen; R R Warrier; K D Kolinsky; V L Wilkinson; C M Dwyer; G F Higgins; F J Podlaski; D A Faherty; P C Familletti; A S Stern; D H Presky Journal: Ann N Y Acad Sci Date: 1996-10-31 Impact factor: 5.691
Authors: Kalliopi Zachou; Cihan Yurdaydin; Uta Drebber; George N Dalekos; Andreas Erhardt; Yilmaz Cakaloglu; Halil Degertekin; Selim Gurel; Stefan Zeuzem; Hakan Bozkaya; Verena Schlaphoff; Hans P Dienes; Thomas C Bock; Michael P Manns; Heiner Wedemeyer Journal: Liver Int Date: 2009-10-16 Impact factor: 5.828
Authors: Elizabeth C Townsend; Grace Y Zhang; Rabab Ali; Pallavi Surana; Marian Firke; Mi Sun Moon; Ma Ai Thanda Han; Meital Gewirtz; James A Haddad; David E Kleiner; Christopher Koh; Theo Heller Journal: Open Forum Infect Dis Date: 2020-10-20 Impact factor: 4.423
Authors: Katie Healy; Anna Pasetto; Michał J Sobkowiak; Chai Fen Soon; Markus Cornberg; Soo Aleman; Margaret Sällberg Chen Journal: Cells Date: 2020-06-16 Impact factor: 6.600
Authors: Ronald E Engle; Davide De Battista; Emily J Danoff; Hanh Nguyen; Zhaochun Chen; Paolo Lusso; Robert H Purcell; Patrizia Farci Journal: mBio Date: 2020-11-17 Impact factor: 7.867